A Study Evaluating Concurrent Chemoradiotherapy Combined With Dual Immune Checkpoint Blockade for Limited-stage Small Cell Lung Cancer
Not Applicable
Not yet recruiting
- Conditions
- Small-Cell Lung Cancer (SCLC)
- Interventions
- Drug: Immuno-chemotherapyRadiation: RadiotherapyDrug: Consolidative therapy
- Registration Number
- NCT07103408
- Lead Sponsor
- Sun Yat-sen University
- Brief Summary
This study will enroll patients with limited-stage small cell lung cancer (SCLC). Patients will receive chemotherapy (etoposide and platinum-based drugs) combined with dual immune checkpoint blockade (PD-1/CTLA-4) and thymosin alpha 1, with a total cycles of 4. Thoracic radiotherapy was performed no later than the three cycle of chemotherapy. Prophylactic cranial irradiation was recommended for patients who received complete response or partial response after chemoradiotherapy. Finally consolidation therapy with dual immune checkpoint blockade (PD-1/CTLA-4) and thymosin alpha 1 was conducted for one year. The study aims to evaluate the efficacy and safety of this treatment regimen.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- NOT_YET_RECRUITING
- Sex
- All
- Target Recruitment
- 56
Inclusion Criteria
- Males or females aged 18 to 75 years or older;
- Patients must have histologically or cytologically confirmed small cell lung cancer (SCLC);
- Stage II-III according to AJCC 8th staging system;
- No prior chemotherapy, radiotherapy, surgery, targeted therapy, or immunotherapy;
- Expected survival ≥ 12 weeks;
- WHO Performance Status (PS) score of 0 or 1;
- Female subjects must not be breastfeeding;
- Women of childbearing potential (WOCBP) must agree to use contraception during the study treatment and for 5 months after the last dose of study drug (i.e., 30 days [one ovulation cycle] plus approximately five half-lives of the study drug);
- Adequate organ and bone marrow function as defined by the following criteria:
- Forced Expiratory Volume in 1 second (FEV1) ≥ 800 mL;
- Absolute neutrophil count ≥ 1.5 × 10⁹/L;
- Platelets ≥ 100 × 10⁹/L;
- Hemoglobin ≥ 9.0 g/dL;
- Creatinine clearance ≥ 50 mL/min as calculated by the Cockcroft-Gault formula (Cockcroft and Gault, 1976);
- Serum bilirubin ≤ 1.5 × upper limit of normal (ULN);
- AST and ALT ≤ 2.5 × ULN.
Exclusion Criteria
- Concurrent enrolment in another clinical study, unless it is an observational(non-interventional) clinical study;
- Mixed small cell and non-small cell lung cancer histology;
- Prior use of anti-PD-1, anti-PD-L1, or anti-CTLA4 antibodies;
- Recent major surgery within 4 weeks prior to entry into the study (excluding the placement of vascular access;
- Active or prior documented autoimmune disease within the past 2 years;
- Active or prior documented inflammatory bowel disease (eg. Crohn's disease, ulcerative colitis);
- History of primary immunodeficiency;
- History of organ transplant that requires therapeutic immunosuppression;
- Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, uncontrolled hypertension, unstable angina pectoris, cardiac arrhythmia, active peptic ulcer disease or gastritis, active bleeding diatheses including any patient known to have hepatitis B, hepatitis C or human immunodeficiency virus (HIV), or psychiatric illness/social situations that would limit compliance with study requirements or compromise the ability of the patient to give written informed consent;
- Known history of tuberculosis;
- History of another primary malignancy within 5 years prior to starting treatment, except for adequately treated basal or squamous cell carcinoma of the skin or cancer of the cervix in situ and the disease under study;
- Female patients who are pregnant, breast-feeding or male or female patients of reproductive potential who are not employing an effective method of birth control.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Arm && Interventions
Group Intervention Description The study group Immuno-chemotherapy Patients will receive chemotherapy (etoposide and platinum-based drugs) combined with dual immune checkpoint blockade (iparomlimab and tuvonralimab) and thymosin alpha 1, with a total cycles of 4. Thoracic radiotherapy was performed no later than the three cycle of chemotherapy. Prophylactic cranial irradiation was recommended for patients who received complete response or partial response after chemoradiotherapy. Finally consolidation therapy with dual immune checkpoint blockade (iparomlimab and tuvonralimab) and thymosin alpha 1 was conducted for one year. The study group Radiotherapy Patients will receive chemotherapy (etoposide and platinum-based drugs) combined with dual immune checkpoint blockade (iparomlimab and tuvonralimab) and thymosin alpha 1, with a total cycles of 4. Thoracic radiotherapy was performed no later than the three cycle of chemotherapy. Prophylactic cranial irradiation was recommended for patients who received complete response or partial response after chemoradiotherapy. Finally consolidation therapy with dual immune checkpoint blockade (iparomlimab and tuvonralimab) and thymosin alpha 1 was conducted for one year. The study group Consolidative therapy Patients will receive chemotherapy (etoposide and platinum-based drugs) combined with dual immune checkpoint blockade (iparomlimab and tuvonralimab) and thymosin alpha 1, with a total cycles of 4. Thoracic radiotherapy was performed no later than the three cycle of chemotherapy. Prophylactic cranial irradiation was recommended for patients who received complete response or partial response after chemoradiotherapy. Finally consolidation therapy with dual immune checkpoint blockade (iparomlimab and tuvonralimab) and thymosin alpha 1 was conducted for one year.
- Primary Outcome Measures
Name Time Method Progression-free survival 2-year PFS measures the time from the start date of treatment to disease progression, death from any cause or last follow up if alive.
- Secondary Outcome Measures
Name Time Method Overall survival 2-year OS measures the time from the start date of treatment to death from any cause or last follow up if alive.
Treatment-related toxicity through study completion, an average of 18 months Treatment-related toxicities were graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) 5.0 toxicity
Trial Locations
- Locations (1)
Sun Yat-sen University Cancer Center
🇨🇳Guangzhou, Guangdong, China
Sun Yat-sen University Cancer Center🇨🇳Guangzhou, Guangdong, ChinaHui Liu, DoctorContact+8687343657liuhuisysucc@126.com